Pearlman B J, Schoenfield L J
Med Clin North Am. 1978 Jan;62(1):87-105. doi: 10.1016/s0025-7125(16)31824-7.
Adequate concentrations of bile acids and phospholipids are necessary to keep cholesterol in solution in bile. When the amount of cholesterol exceeds the capacity of bile acids and phospholipids to keep the cholesterol in micellar solution, bile becomes supersaturated; then, under appropriate conditions, cholesterol crystals form and gallstones may develop. Current dissolution therapy is aimed at desaturating the bile, thereby shifting the equilibrium of cholesterol from a crystalline phase back toward a micellar state, thus permitting gallstones to dissolve. Chenodeoxycholic acid is the drug being most extensively tested for efficacy in dissolution; at present, it is successful in about 60 per cent of cases. The primary mechanism of action appears to be suppression of biliary secretion of cholesterol. Further experience is needed to confirm the safety of chenodeoxycholic acid, to gain more precision in patient selection, and to determine ideal dose. The role of chenodeoxycholic acid in prophylaxis and in prevention of recurrence needs further study. Other potential agents for dissolution also deserve investigation.
胆汁中要有足够浓度的胆汁酸和磷脂才能使胆固醇保持溶解状态。当胆固醇量超过胆汁酸和磷脂将胆固醇保持在胶态溶液中的能力时,胆汁就会过度饱和;然后,在适当条件下,胆固醇结晶形成,胆结石可能发展。目前的溶石疗法旨在降低胆汁的饱和度,从而使胆固醇平衡从结晶相转回到胶态状态,从而使胆结石溶解。鹅去氧胆酸是溶石疗效方面接受最广泛测试的药物;目前,约60%的病例治疗成功。主要作用机制似乎是抑制胆固醇的胆汁分泌。需要进一步积累经验以证实鹅去氧胆酸的安全性,更精确地选择患者,并确定理想剂量。鹅去氧胆酸在预防和防止复发方面的作用需要进一步研究。其他潜在的溶石药物也值得研究。